Elad Sharon, Clinical and Translational Director, Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Co-Chair, Alliance Immuno-Oncology Committee at Alliance for Clinical Trials in Oncology, shared a post by Patrick Hwu, President and CEO at Moffitt Cancer Center, adding:
“Honored by this recognition from the world-renowned and esteemed Patrick Hwu. He is both an amazing researcher and one of the most supportive leaders in med onc and immunology.”
Quoting Patrick Hwu‘s post:
“Follow Friday
Elad Sharon is a medical oncologist at the Dana-Farber Cancer Institute, where he is the Clinical and Translational Director of the Immunotherapy Toxicity Program and a Member of the Faculty of Medicine at Harvard Medical School. Dr. Sharon is seeking to develop innovative clinical trials to better understand the side effects associated with immune checkpoint inhibitors and other immunotherapy agents.”